Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380674 | 1.00 | ADRB2 (0.39) | ADRB2ADRB1PDE2AHDAC1HDAC6 | |
| SCHEMBL13238823 | 0.85 | CA1 (0.43) | ADRB2ADRB1PDE2A | |
| SCHEMBL2948980 | 0.85 | CA1 (0.43) | ADRB2ADRB1PDE2A | |
| SCHEMBL18925631 | 0.82 | ADRB2 (0.40) | ADRB2ADRB1HDAC1HDAC6DPP4 | |
| SCHEMBL7804306 | 0.82 | CES2 (0.39) | ADRB2PDE2ADPP4 | |
| SCHEMBL7795357 | 0.82 | CES2 (0.39) | ADRB2PDE2ADPP4 | |
| SCHEMBL4087773 | 0.82 | CES2 (0.39) | ADRB2PDE2ADPP4 | |
| SCHEMBL5386511 | 0.80 | SIGMAR1 (0.43) | ADRB2 | |
| Hydrochloric Acid SCHEMBL7787647 | 0.80 | CES2 (0.38) | ADRB2PDE2ADPP4 | |
| SCHEMBL19654073 | 0.80 | ADRB2 (0.36) | ADRB2PDE2AHDAC1HDAC6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | AMOREPACIFIC CORPORATION (KR) | 2019-11-19 | — | — | US | disclosed |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2017-11-30 | — | — | US | disclosed |
| EP-1641752-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004110997-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | DHCR24, SRR, ACMSD | ADRB2 1629/4885ADRB1 1561/4885PDE2A 3312/4885 |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | DHCR24, SRR, ACMSD | ADRB2 1629/4885ADRB1 1561/4885PDE2A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.